Instead in several neuromuscular disorders, such as spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and CHP1-associated ataxia, PLS3 overexpression acts as a protective modifier. Here, PLS3 is linked to spinal muscular atrophy.